RECRUITING

Aromatherapy Inhaler Use for HSCT Distress

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).

Official Title

Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress

Quick Facts

Study Start:2025-06-16
Study Completion:2026-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05302583

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Autologous and Allogeneic patients admitted to E1 for planned HSCT
  2. * Patients with hematologic malignancies requiring HSCT
  3. * No allergies to lavender or peppermint essential oils
  4. * Must have received chemotherapy during preparative regimen (single or multi-agent regimen)
  5. * Adult patient over 18 years of age
  6. * Able to speak, read, and comprehend English
  7. * Willing and capable of providing informed consent
  1. * Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion
  2. * Patients receiving a transplant for a germ cell tumor diagnosis
  3. * Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)
  4. * Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4
  5. * History of scleroderma
  6. * History of atrial fibrillation
  7. * Known history of G6PD deficiency
  8. * Allergic to lavender or peppermint essential oils
  9. * Pediatric patient 18 years of age or less
  10. * Unable to speak, read, and comprehend English
  11. * Unwilling or incapable of providing informed consent

Contacts and Locations

Study Contact

Aubrey Florom-Smith, PhD, RN
CONTACT
650-285-9512
aubsmith@stanford.edu

Principal Investigator

Anna Oh, PhD, MPH, RN
PRINCIPAL_INVESTIGATOR
Stanford University

Study Locations (Sites)

Stanford University
Stanford, California, 94305
United States

Collaborators and Investigators

Sponsor: Stanford University

  • Anna Oh, PhD, MPH, RN, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-16
Study Completion Date2026-03

Study Record Updates

Study Start Date2025-06-16
Study Completion Date2026-03

Terms related to this study

Additional Relevant MeSH Terms

  • Cancer Distress
  • Cancer Coping
  • Hematopoetic Stem Cell Transplant
  • Aromatherapy